High NOTCH3 expression further negatively correlated with other, established and widely used predictive biomarkers for the success of ICIs, including high tumour mutation burden (TMB) and the innate anti-PD-1 resistance (IPRES) signature. This evidence concerns the gene NOTCH3 and neoplasm.